Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31533717 | 0.85 | DGAT1 (0.41) | NPC1DGAT1MAPTHTT | |
| SCHEMBL2377093 | 0.85 | DGAT1 (0.41) | NPC1DGAT1MAPTHTT | |
| SCHEMBL12389426 | 0.80 | NPC1 (0.36) | NPC1DGAT1MAPTHTT | |
| SCHEMBL30867590 | 0.78 | NPC1 (0.35) | NPC1DGAT1MAPTALOX5APFEN1 | |
| SCHEMBL12389653 | 0.77 | NPC1 (0.41) | NPC1DGAT1MAPTALOX5APFEN1 | |
| SCHEMBL18210176 | 0.75 | HTT (0.36) | NPC1DGAT1MAPTHTT | |
| SCHEMBL21463677 | 0.75 | DGAT1 (0.39) | NPC1DGAT1MAPTHTT | |
| SCHEMBL2359261 | 0.75 | DGAT1 (0.39) | NPC1DGAT1MAPTALOX5APFEN1 | |
| SCHEMBL2376267 | 0.75 | NPC1 (0.37) | NPC1DGAT1MAPT | |
| SCHEMBL1192594 | 0.74 | DGAT1 (0.38) | NPC1DGAT1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | NPC1 4394/4885DGAT1 4356/4885MAPT 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.